3-Naphthalen-1-yl-pyrrolidine | 178483-14-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-Naphthalen-1-yl-pyrrolidine
• 英文别名: 3-(1-Naphthyl)pyrrolidine；3-naphthalen-1-ylpyrrolidine
• CAS: 178483-14-2
• 化学式: C₁₄H₁₅N
• 分子量: 197.28
• InChiKey: KTMCVZGLGDBGJZ-UHFFFAOYSA-N

物化性质

• 沸点：
  352.9±21.0 °C(Predicted)
• 密度：
  1.077±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  1-碘代丙烷 、 3-Naphthalen-1-yl-pyrrolidine 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 12.0h， 以82%的产率得到3-naphthalen-1-yl-1-propylpyrrolidine
  参考文献：
  名称：

  Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity.

  摘要：

  A series of 3-arylpyrrolidines has been synthesised via palladium catalyzed arylation and evaluated for dopaminergic and serotonergic activity in vitro and in vivo. Compounds substituted by electron withdrawing groups on the meta position of the aromatic ring, were found to be preferential dopamine autoreceptor antagonists. (C) 1997, Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(96)00618-x
• 作为产物：
  描述：

  Methyl 3-naphthalen-1-ylpyrrolidine-1-carboxylate 在 盐酸 作用下， 以 甲醇 为溶剂， 生成 3-Naphthalen-1-yl-pyrrolidine
  参考文献：
  名称：

  Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity.

  摘要：

  A series of 3-arylpyrrolidines has been synthesised via palladium catalyzed arylation and evaluated for dopaminergic and serotonergic activity in vitro and in vivo. Compounds substituted by electron withdrawing groups on the meta position of the aromatic ring, were found to be preferential dopamine autoreceptor antagonists. (C) 1997, Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(96)00618-x

文献信息

• Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
  申请人：Skolnick Phil

  公开号：US20070082940A1

  公开（公告）日：2007-04-12

  The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.

  本发明提供了新型的、多取代的1-芳基-3-氮杂双环[3.1.0]己烷，以及制备这些化合物的相关过程和中间体，以及使用这些化合物治疗和/或预防中枢神经系统（CNS）疾病，包括抑郁症和焦虑症的组合物和方法。
• Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders
  申请人：Skolnick Phil

  公开号：US20090233978A1

  公开（公告）日：2009-09-17

  The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.

  本发明提供了新颖的多取代的1-芳基-3-氮杂双环[3.1.0]己烷，以及制备这些化合物的相关过程和中间体，以及使用这些化合物进行中枢神经系统（CNS）疾病的治疗和/或预防，包括抑郁症和焦虑症的组合物和方法。
• Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders
  申请人：SKOLNICK Phil

  公开号：US20120302619A1

  公开（公告）日：2012-11-29

  The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.

  该发明提供了一种新型的多取代的1-芳基-3-氮杂双环[3.1.0]己烷，以及制备这些化合物的相关过程和中间体，以及使用这些化合物进行治疗和/或预防中枢神经系统（CNS）疾病，包括抑郁症和焦虑症的组合物和方法。
• Ring-substituted 2-amino 1,2,3,4-tetra-hydronaphthalenes and 3-aminochromanes
  申请人：ELI LILLY AND COMPANY

  公开号：EP0385658A1

  公开（公告）日：1990-09-05

  The present invention provides novel ring-­substituted 2-amino-1,2,3,4-tetrahydronaphthalenes which exhibit binding activity at the serotonin 1A receptor and 3-aminochromane intermediates. The pharmaceutical compounds have the formula in which R is C₁-C₄ alkyl, allyl, or cyclopropylmethyl; R₁ is hydrogen, C₁-C₄ alkyl, allyl, cyclopropyl­methyl, or aryl(C₁-C₄-alkyl); R₂ is hydrogen or methyl; X is -CH₂- or -O-; R₃ is C₁-C₈ alkyl, aryl, substituted aryl, aryl(C₁-C₄-alkyl), substituted aryl(C₁-C₄ alkyl), or C₅-C₇ cycloalkyl; n is 0, 1, or 2; and pharmaceutically acceptable acid addition salts thereof.

  本发明提供了新型环取代的 2-氨基-1,2,3,4-四氢萘，它们在血清素 1A 受体和 3-氨基色满中间体上表现出结合活性。这些药物化合物的化学式为 其中 R 是 C₁-C₄ 烷基、烯丙基或环丙基甲基； R₁ 是氢、C₁-C₄ 烷基、烯丙基、环丙基甲基或芳基（C₁-C₄-烷基）； R₂ 是氢或甲基； X 是-CH₂- 或-O-； R₃ 是 C₁-C₈ 烷基、芳基、取代的芳基、芳基(C₁-C₄-烷基)、取代的芳基(C₁-C₄ 烷基)或 C₅-C₇ 环烷基； n 为 0、1 或 2； 及其药学上可接受的酸加成盐。
• Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
  申请人：ELI LILLY AND COMPANY

  公开号：EP0343830B1

  公开（公告）日：1994-07-13